Theriva Biologics, Inc.
TOVX- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000894158
No open-market purchases or sales by Theriva Biologics, Inc. insiders were filed in the last 90 days; 26 institutions reported holding it in 13F filings for Q2 2026, worth $495.5K in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Theriva Biologics, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −3 vs. Q4 2022
- Shares held
- 1.04M
- −13.2K (−1.3%) vs. Q4 2022
- Total value
- $724.6K
- +$247.5K (+51.9%) vs. Q4 2022
- New holders
- 2
- 2 more added
- Sold out
- 5
- 2 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting TOVX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 26 | $495.5K |
| Q1 2026 | 22 | $385.4K |
| Q4 2025 | 21 | $272.4K |
| Q3 2025 | 20 | $177.0K |
| Q2 2025 | 17 | $126.3K |
| Q1 2025 | 11 | $209.8K |
| Q4 2024 | 10 | $60.3K |
| Q3 2024 | 18 | $678.6K |
| Q2 2024 | 22 | $327.6K |
| Q1 2024 | 24 | $366.3K |
| Q4 2023 | 24 | $452.3K |
| Q3 2023 | 21 | $572.8K |
| Q2 2023 | 18 | $1.01M |
| Q1 2023 | 19 | $724.6K |
| Q4 2022 | 22 | $477.1K |
| Q3 2022 | 26 | $1.15M |
| Q2 2022 | 33 | $2.51M |
| Q1 2022 | 35 | $3.17M |
| Q4 2021 | 35 | $3.24M |
| Q3 2021 | 36 | $3.32M |
| Q2 2021 | 31 | $3.91M |
| Q1 2021 | 32 | $5.80M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Theriva Biologics, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 525,367 | $366.9K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 190,169 | $132.8K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 116,301 | $81.2K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 48,691 | $34.0K | 0.00% | 00.0% | Unchanged |
| Northern Trust Corp | 35,699 | $24.9K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 34,710 | $24.0K | 0.00% | +2,200+6.8% | Added |
| Bridgeway Capital Management, LLC | 28,528 | $19.9K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 20,597 | $14.4K | 0.00% | +20,597 | New |
| Charles Schwab Investment Management Inc | 13,566 | $9.47K | 0.00% | 00.0% | Unchanged |
| Fisher Asset Management, LLC | 12,569 | $8.78K | 0.00% | 00.0% | Unchanged |
| Susquehanna International Group, LLP | 10,687 | $7.46K | 0.00% | +10,687 | New |
| IFP Advisors, Inc | 382 | $572 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 110 | $77 | 0.00% | +2+1.9% | Added |
| Advisor Group Holdings, Inc. | 47 | $32 | 0.00% | 00.0% | Unchanged |
| Bank of America Corp | 21 | $14 | 0.00% | −3−12.5% | Reduced |
| Steward Partners Investment Advisory, LLC | 14 | $10 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 10 | $7 | 0.00% | −661−98.5% | Reduced |
| Royal Bank of Canada | 7 | $0 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 145 | $0 | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 0 | $0 | 0.00% | −28,972−100.0% | Sold out |
| Two Sigma Advisers, LP | 0 | $0 | 0.00% | −11,990−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −5,015−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −9−100.0% | Sold out |
| Rockefeller Capital Management L.P. | 0 | $0 | 0.00% | −26−100.0% | Sold out |